A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
This research study is looking at a medicine called tolvaptan for children and teenagers (from 28 days old up to just under 18 years) who have a kidney condition called Autosomal Recessive Polycystic Kidney Disease (ARPKD). The main purpose is to check if tolvaptan is safe for them. We know that this medicine has helped adults with a similar kidney disease (ADPKD) by slowing down kidney damage. This study will follow participants for 18 months, with the total study lasting about three and a half years. All participants will receive tolvaptan, and doctors will carefully monitor how they get on. This is an important step to understand if tolvaptan could be a future treatment option for young people with ARPKD.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is about a medicine called tolvaptan, and it's being tested in children and teenagers (from 28 days old up to just under 18 years) who have a specific kidney condition called Autosomal Recessive Polycystic Kidney Disease, or ARPKD. ARPKD is a condition where many cysts (fluid-filled sacs) grow in the kidneys, which can stop them from working properly over time.
The main aim of this study is to find out if tolvaptan is safe for young people with ARPKD. We already know that tolvaptan has been helpful for adults with a very similar kidney condition called ADPKD. In adults, it helped to slow down the damage to their kidneys. Researchers hope to learn if it could offer similar benefits, and most importantly, be safe for children with ARPKD.
Taking part would mean receiving the tolvaptan medicine and having regular checks over 18 months. The research team will be looking very closely at how participants respond to the treatment and ensuring their safety throughout the study. This kind of research is vital for finding new ways to help children with ARPKD.
النقاط الرئيسية
- This study is testing if a medicine called tolvaptan is safe for children with ARPKD.
- Tolvaptan has helped adults with a similar kidney condition by slowing down kidney damage.
- Children aged 28 days to under 18 years with ARPKD may be able to join.
- Participants will receive tolvaptan and be followed closely for 18 months.
- The study aims to find new potential treatments for children with ARPKD.
من قد يكون مؤهلاً؟
To join this study, children need to be between 28 days old and just under 18 years old, and have been diagnosed with ARPKD. Their parents or legal guardians must be able to understand and sign consent forms, and everyone involved must be able to follow the study rules. If the child is old enough according to local laws, they will also be asked to agree to take part.
There are several reasons why a child might not be able to join. For example, very premature babies (born at 32 weeks or less) who are less than 12 weeks old cannot take part. Children who already need dialysis or have had a kidney transplant, or those with very poor liver function or certain other health issues like severe heart problems, will not be able to participate. Also, if a child cannot be properly monitored for how much fluid they drink and pass, or if they have certain blood problems, they would not be suitable.
Children currently taking other experimental medicines, or those who need continuous breathing support (ventilator), or certain specific medications that could interfere with the study drug, also cannot join. For girls, they cannot be breastfeeding or pregnant. The study team will review all of these details carefully with you to see if your child is a good fit.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- Is my child between 28 days and less than 18 years old?
- Does my child have a diagnosis of ARPKD?
- Is my child currently on dialysis or has had a kidney transplant?
- Does my child have any other severe health problems as listed by the doctor?
- Can we commit to regular hospital visits and follow-up for 18 months?
ماذا يتضمن المشاركة؟
If your child takes part in this study, they will receive the study medicine, tolvaptan, which comes as either a liquid ('suspension') or tablets. They will be followed very closely for 18 months. This will involve regular visits to the hospital for check-ups, blood tests, and other assessments to see how they are responding to the medicine and to monitor their health generally.
The total study is expected to last about three and a half years from start to finish, with your child's individual treatment and follow-up lasting 18 months. The study is 'open-label,' meaning both you and the study doctors will know that your child is receiving tolvaptan. There won't be a placebo group. The doctors will also carefully monitor your child’s fluid intake and output throughout the study.
المخاطر والفوائد المحتملة
المواقع (23)
- Children's National Medical Centerالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة· التوظيف
- مستشفى جامعة إيموريالرمز البريدي المؤكدأتلانتا، الولايات المتحدة· منسحب
- Northwestern University Feinberg School of Medicine - Ann & Robert H. Lurie Children's Hospital of Chicago - Neonatologyالرمز البريدي المؤكدشيكاغو، الولايات المتحدة· منسحب
- Riley Hospital for Childrenالرمز البريدي المؤكدإنديانابوليس، الولايات المتحدة· منسحب
- Children's Hospital - New Orleansالرمز البريدي المؤكدنيو أورلينز، الولايات المتحدة· منسحب
- Johns Hopkins Pediatric Specialty Clinicالرمز البريدي المؤكدبالتيمور، الولايات المتحدة· التوظيف
- C.S. Mott Children's Hospitalالرمز البريدي المؤكدآن آربر، الولايات المتحدة· التوظيف
- مايو كلينك - روتشسترالرمز البريدي المؤكدروتشستر، الولايات المتحدة· التوظيف
- مركز سينسيناتي الطبي للأطفالالرمز البريدي المؤكدسينسيناتي، الولايات المتحدة· التوظيف
- عيادة كليفلاندالرمز البريدي المؤكدكليفلاند، الولايات المتحدة· التوظيف
- Children's Hospital of Pittsburgh of UPMCالرمز البريدي المؤكدبيتسبرغ، الولايات المتحدة· منسحب
- Primary Children's Hospitalالرمز البريدي المؤكدسولت ليك سيتي، الولايات المتحدة· منسحب
أسئلة شائعة
What is ARPKD?
ARPKD is a kidney condition that affects children. It causes many small, fluid-filled sacs (cysts) to grow in the kidneys, which can stop them from working properly.
What is tolvaptan?
Tolvaptan is a medicine that has been shown to help adults with a similar kidney condition by slowing down kidney damage. This study is testing if it's safe for children with ARPKD.
Will my child definitely get the medicine?
Yes, if your child qualifies for this study and you agree to participate, they will receive the tolvaptan medicine.
كم من الوقت سيبقى طفلي في الدراسة؟
Your child will receive the medicine and be followed for 18 months.
Can I take my child out of the study if we change our mind?
Yes, you can choose to withdraw your child from the study at any time, and it won't affect their regular medical care.
كيفية معرفة المزيد
Otsuka Call Center
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.